CLINICAL TRIALS PROFILE FOR ULIXERTINIB
✉ Email this page to a colleague
Clinical Trials for Ulixertinib
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT02465060 ↗ | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | Recruiting | National Cancer Institute (NCI) | Phase 2 | This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma. |
| NCT02994732 ↗ | Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled BVD-523 in Volunteers | Completed | BioMed Valley Discoveries, Inc | Phase 1 | The primary objective of this study is to characterize the metabolic disposition, pharmacokinetics (PK), and routes of elimination of [14C]-labeled BVD-523 after administration of a single, oral dose to healthy male subjects. The secondary objective of this study is to evaluate the safety and tolerability of a single oral dose of [14C]-labeled BVD-523 in healthy male subjects. |
| NCT03155620 ↗ | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | Recruiting | National Cancer Institute (NCI) | Phase 2 | This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas. |
| NCT03417739 ↗ | A Phase II Study of BVD-523 in Metastatic Uveal Melanoma | Active, not recruiting | BioMed Valley Discoveries, Inc | Phase 2 | This research study is studying a targeted therapy called BVD-523 as a possible treatment for advanced uveal melanoma. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Ulixertinib
Condition Name
Clinical Trial Locations for Ulixertinib
Trials by Country
Clinical Trial Progress for Ulixertinib
Clinical Trial Phase
Clinical Trial Sponsors for Ulixertinib
Sponsor Name
